肺腺癌に対する術後補助化学療法の検討 : 第1次研究:MMC+TegafurとMMC+UFTの比較試験(第2報) A Randomized Controlled Postoperative Adjuvant Chemotherapy Trial of MMC+Tegafur and MMC+UFT for Adenocarcinoma of the Lung-First Study (Second Report) :

この論文にアクセスする

この論文をさがす

著者

抄録

西日本地区30施設の共同研究により,肺癌の治癒切除例に対する補助化学療法の有用性を検討した.このtrialが終了した後5年の観察期間が経過したのでその成績を報告する.対象は絶対的治癒切除,相対的治癒切除となった肺腺癌であり,A群はMMC(20+10mg)+tegafur600mg1年間経口投与,B群はMMC(20+10mg)+UFT400-600mg1年間経口投与とした.1982年11月から1985年11月までにA群113例,B群111例の計224例が集積された.不適格例が43例であり,A群88例,B群93例を解析対象とした.背景因子には差は認めなかった.成績は5年生存率および5年健存率で検討した.両群の全症例の5年生存率はA群64.3%,B群55.6%で有意差は認めず,健存率でも差はなかった.後層別解析で,N2症例において5年生存率および5年健存率とも,B群が良好であった(p=0.029,p=0.048).

The usefulness of adjuvant chemotherapy in patients with pulmonary carcinoma undergoing curative resection was jointly studied by 30.institutions in Western Japan. The results of this trial after a 5-year follow-up are reported here. The subjects were patients with pulmonary adenocarcinoma who underwent absolutely or relatively curative resection. They were treated with 20+10mg MMC, plus 600mg tegafur orally for one year(Group A) or with 20+10mg MMC, plus 400-600mg UFT orally for one year (Group B). Between November 1982 and November 1985, 224 patients received this therapy (113 in Group A, and 111 in group B). Excluding 43 cases which were judged inappropriate for evaluation, 88 patients in Group A and 93 in Group B were evaluated. There was no significant difference in any background variable between the two groups. The overall 5-year survival rate did not significantly differ between Group A (64.3%) and Group B (55.6%). The overall 5 year disease-free rate also did not significantly differ between the two groups. In stratified analysis, N2 cases in group B had higher 5-year survival and recurrence-free rates than those in Group A (p=0.029 and 0.048, respectively).

収録刊行物

  • 肺癌

    肺癌 31(7), 1011-1019, 1991-12-20

    日本肺癌学会

被引用文献:  1件中 1-1件 を表示

各種コード

  • NII論文ID(NAID)
    110003142735
  • NII書誌ID(NCID)
    AN00203978
  • 本文言語コード
    JPN
  • 資料種別
    雑誌論文
  • ISSN
    03869628
  • データ提供元
    CJP引用  NII-ELS 
ページトップへ